Pricing Log in Create free account

Edgewise Therapeutics, Inc. (EWTX) vs Telix Pharmaceuticals Limited (TLX)

Edgewise Therapeutics, Inc. and Telix Pharmaceuticals Limited are both Biotechnology companies. Edgewise Therapeutics, Inc. is the larger, with a market value of $4.2B against $3.6B — 1.2× the size. Across the 7 metrics below, Edgewise Therapeutics, Inc. leads on 4 and Telix Pharmaceuticals Limited on 3.

Valuation

Metric EWTX TLX Biotechnology median
P/E n/m — 8.50
P/S n/m — 9.71
P/B 8.94 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (4.97%) — (33.15%)
Free cash flow yield (3.97%) 0.00% (25.50%)

Profitability

Metric EWTX TLX Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (38.03%) 0.00% (56.36%)
Return on assets (36.09%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EWTX TLX Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (12.41%) (120.00%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric EWTX TLX Biotechnology median
Debt to equity 0.00 1.18 0.00
Current ratio 16.24 2.01 4.72
Net debt to EBITDA 2.69 6.25 0.96

Dividend

Metric EWTX TLX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric EWTX TLX Biotechnology median
Market cap 4.15b 3.60b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack